Skip to main content

Table 2 Patient Demographic and Baseline Characteristics

From: Clinical impact of a metagenomic microbial plasma cell-free DNA next-generation sequencing assay on treatment decisions: a single-center retrospective study

Total patients

N = 80

Age (years), mean (± SD)

54.3(± 15.4)

Gender, n (%)

 Female

32 (40)

 Male

48 (60)

Reason for mcfDNA Assay, n (%)

 Microbiologic diagnosis unknown

74 (78)

 Avoid invasive diagnostic procedure

13 (14)

 Confirmatory test

5 (5)

 Early diagnosis

3 (3)

Types of Clinical Impact, n (%)

 Negative

2 (3)

 Positive

34 (43)

 Uncertain or No impact

44 (55)

Consistency with final clinical diagnosis, n (%)

 Yes

52 (65)

 No

25 (31)

 NA

3 (4)

  1. SD—Standard deviation; NA—Not applicable because the KT assay did not meet quality control and did not provide a result; mcfDNA—microbial cell-free DNA; Clinical Impact—defined in Table 1